<DOC>
	<DOCNO>NCT02283788</DOCNO>
	<brief_summary>A randomized , double-blind , placebo-controlled open label active-controlled , 4 period crossover trial evaluate effect eslicarbazepine acetate cardiac repolarization healthy adult men woman</brief_summary>
	<brief_title>Trial Evaluate Effect Eslicarbazepine Acetate Cardiac Repolarization</brief_title>
	<detailed_description>The purpose randomize , double-blind , placebo-controlled open label active-controlled , 4 period crossover study evaluate effect therapeutic supra-therapeutic dos eslicarbazepine acetate placebo correct time-matched change baseline use individually correct QT ( QTcI ) interval duration adult healthy volunteer .</detailed_description>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Be healthy male female 18 45 year age . Women require postmenopausal ( 12 month since last period ) ; surgically sterile ( hysterectomy tubal ligation least 6 month prior enrollment ) ; use intrauterine device ; double barrier ( i.e . diaphragm spermicide plus male condom ) nonhormonal contraceptive therapy duration trial require negative pregnancy test screen upon checkin study facility . Have BMI within range 1830 kg/m2 . Be able communicate effectively study personnel . Have significant disease abnormal laboratory value determine medical history , physical examination laboratory evaluation , conduct screen visit admission clinic . Have normal 12lead electrocardiogram , without clinically significant abnormality rate , rhythm conduction . Be nonsmoker define smoke past 6 month . Be adequately informed nature risk study give write informed consent prior study entry . Known hypersensitivity allergy moxifloxacin , eslicarbazepine acetate relate compound carbamazepine , oxcarbazepine , licarbazepine . Women pregnant breast feeding . Any disease condition ( medical surgical ) , opinion investigator , might compromise hematologic , cardiovascular , pulmonary , renal , gastrointestinal , hepatic , central nervous system ; condition may interfere absorption , distribution , metabolism excretion study drug , place subject increase risk . A sustained supine systolic blood pressure &gt; 140 mmHg &lt; 100mm Hg diastolic blood pressure &gt; 95 mmHg screen baseline . A rest ECG heart rate &lt; 50 bpm &gt; 100 bpm .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>